Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
P/S ratio for Lexicon Pharmaceuticals, Inc. (LXRX)
P/S ratio as of 2023: 281.00
According to Lexicon Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 281.00. At the end of 2022 the company had a P/S ratio of 2277.34.
P/S ratio history for Lexicon Pharmaceuticals, Inc. from 1999 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 281.00 |
| 2022 | 2277.34 |
| 2021 | 1925.73 |
| 2020 | 15.80 |
| 2019 | 1.37 |
| 2018 | 11.11 |
| 2017 | 11.50 |
| 2016 | 17.24 |
| 2015 | 10.60 |
| 2014 | 21.28 |
| 2013 | 415.66 |
| 2012 | 993.80 |
| 2011 | 237.74 |
| 2010 | 88.85 |
| 2009 | 23.11 |
| 2008 | 5.93 |
| 2007 | 6.03 |
| 2006 | 3.32 |
| 2005 | 3.08 |
| 2004 | 7.96 |
| 2003 | 7.81 |
| 2002 | 7.02 |
| 2001 | 1.90 |
| 2000 | 47.86 |
| 1999 | 97.86 |